Document:

exv10w4

Exhibit 10.4

EXECUTION COPY

AMENDMENT #3 TO AMENDED AND RESTATED 

CREDIT AND SECURITY AGREEMENT, 

AMENDMENT #1 TO AMENDED AND RESTATED RECEIVABLES SALE 

 AGREEMENT and RESTATEMENT OF AMENDED FEE LETTERS

     THIS AMENDMENT #3 TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT, AMENDMENT #1 TO
AMENDED AND RESTATED RECEIVABLES SALE AGREEMENT and RESTATEMENT OF AMENDED FEE LETTERS (this
“Amendment”) is entered into by the undersigned parties as of August 4, 2010 with respect to

     (1) the Amended and Restated Credit and Security Agreement dated as of November 7, 2007 by and
among Boston Scientific Funding LLC, a Delaware limited liability company (“Borrower”), Boston
Scientific Corporation (“BSC”), a Delaware corporation, as initial Servicer, Old Line Funding, LLC,
a Delaware limited liability company (“Old Line”), Victory Receivables Corporation, a Delaware
corporation (“Victory”), The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, individually as a
Liquidity Bank for Victory and as Victory Agent and Royal Bank of Canada, a Canadian chartered bank
acting through a New York branch, in its capacity as Liquidity Bank for Old Line, as Old Line Agent
and as Administrative Agent, as heretofore amended (the “Credit and Security Agreement”); and

     (2) the Receivables Sale Agreement described in the Credit and Security Agreement, as
heretofore amended (the “Receivables Sale Agreement”); and

     (3) each of the Amended Fee Letters described in the Credit and Security Agreement, as
restated pursuant hereto (the “Fee Letters”).

     Unless defined elsewhere herein, capitalized terms used in this Amendment shall have the
meanings assigned to such terms in the Credit and Security Agreement.

RECITALS

     WHEREAS, the Borrower, the initial Servicer, Victory, Old Line, The Bank of Tokyo-Mitsubishi
UFJ, Ltd., New York Branch, individually as a Liquidity Bank and as Victory Agent and Royal Bank of
Canada, individually, as a Liquidity Bank and as Administrative Agent entered into the Credit and
Security Agreement;

     WHEREAS, the Borrower, as buyer, and BSC, as seller, have entered into the Receivables Sale
Agreement; and

     WHEREAS, the Borrower has requested that the Credit and Security Agreement and the Receivables
Sale Agreement be amended as hereinafter set forth; and

     WHEREAS, as a condition to agreeing to the requested amendments to the Credit and Security
Agreement and to the Receivables Sale Agreement, the Agents have requested the restatement of the
Fee Letters hereinafter set forth.

 

 

     NOW THEREFORE, in consideration of the mutual execution hereof and other good and valuable
consideration, the parties hereto agree as follows:

     1. Amendments to Credit and Security Agreement.

          (a) Clause (i) of Section 6.1(o) of the Credit and Security Agreement is hereby
amended to read as follows:

(i) in favor of an Originator in accordance with the Contracts or in connection with
an asset purchase or other similar agreement pursuant to which Acquired Receivables
are purchased,

          (b) Section 7.1(h) of the Credit and Security Agreement is hereby amended by replacing the
period at the end thereof with the following new proviso:

; provided that with respect to Acquired Receivables, such Loan Party may instruct
the Obligors thereof to continue to pay Collections to any lockbox or bank account
to which Collections for such Acquired Receivables were paid by the Obligors prior
to such receivables becoming Acquired Receivables, so long as any and all payments
or balances in such lockbox or bank account on any day are automatically transferred
within two (2) Business Days to a Lockbox listed on Exhibit IV hereto which is
subject to a Collection Account Agreement or a Collection Account listed on Exhibit
IV hereto which is subject to a Collection Account Agreement.

          (c) The second sentence of Section 7.1(m) of the Credit and Security Agreement is hereby
amended to read as follows:

In the event any payments relating to the Collateral are remitted directly to
Borrower or any Affiliate of Borrower or, except in the case of payments relating to
Acquired Receivables which are governed by Section 7.1(h) and 8.2(b), are deposited
to a lockbox or collection account not listed on Exhibit IV hereto and not covered
by a Collection Account Agreement, Borrower will remit (or will cause all such
payments to be remitted) directly to a Collection Bank and deposited into a
Collection Account within two (2) Business Days following receipt thereof, and, at
all times prior to such remittance, Borrower will itself hold or, if applicable,
will cause such payments to be held in trust for the exclusive benefit of the
Administrative Agent and the Lenders.

          (d) Section 8.2(b) of the Credit and Security Agreement is hereby amended by replacing the
period at the end of the first sentence thereof with the following new proviso:

 

 

; provided that with respect to Acquired Receivables, the Servicer may instruct the
Obligors thereof to continue to pay Collections to any bank account to which
Collections for such Acquired Receivables were paid by the Obligors prior to such
receivables becoming Acquired Receivables, so long as any and all payments or
balances in such bank account on any day are automatically transferred within two
(2) Business Days to a Lockbox listed on Exhibit IV hereto which is subject to a
Collection Account Agreement or a Collection Account listed on Exhibit IV hereto
which is subject to a Collection Account Agreement.

          (e) Section 10.1(a)(A) of the Credit and Security Agreement is hereby amended to read as
follows:

     (A) the creation of any Lien on the Receivables, or transfer by any Loan Party
of any interest in the Collateral, other than as provided in the Transaction
Documents;

          (f) The definitions of “Applicable Stress Factor” and “BSX Credit Agreement” in Exhibit I to
the Credit and Security Agreement are hereby deleted in their entirety and replaced with the
following:

     “Applicable Stress Factor” means 2.25.

     “BSX Credit Agreement” means that certain Credit Agreement dated as of June 23, 2010 in
effect on the date hereof among (i) BSX, as the “Borrower” thereunder, (ii) BSC
International Holding Limited, as the “Term Loan Borrower” thereunder, (iii) the several
lenders party thereto, (iv) JPMorgan Chase Bank, N.A., as “Syndication Agent” thereunder,
(v) Bank of America, N.A., as “Administrative Agent” thereunder , (vi) Banc of America
Securities LLC and J.P.Morgan Securities Inc., as “Joint Lead Arrangers and Joint
Bookrunners” thereunder, (vii) Barclays Capital, BNP Paribas Securities Corp., Citigroup
Global Markets Inc., Deutsche Bank Securities Inc., RBS Securities Inc., and UBS Securities
LLC, as “Joint Lead Arrangers” thereunder, and (viii) Barclays Bank PLC, BNP Paribas,
Citibank N.A., Deutsche Bank Securities Inc., The Royal Bank of Scotland PLC, and UBS
Securities LLC, as “Documentation Agents” thereunder.

          (g) Each of clauses (l), (m) and (p) of the definition of “Eligible Receivable” in Exhibit I
to the Credit and Security Agreement is hereby amended to include the originators of Acquired
Receivables and these clauses now read as follows:

     (l) which was generated by an Eligible Originator (or, in the case of an
Acquired Receivable, a Subsidiary of a Seller under the Receivables Sale Agreement)
in the ordinary course of its business,

     (m) which arises solely from the sale of goods or the provision of services to
the related Obligor by the applicable Originator (or, in the case of an Acquired
Receivable, a Subsidiary of a Seller under the Receivables Sale Agreement), and not
by any other Person (in whole or in part),

 

 

     (p) as to which the applicable Originator (or, in the case of an Acquired
Receivable, a Subsidiary of a Seller under the Receivables Sale Agreement) has
satisfied and fully performed all obligations on its part with respect to such
Receivable required to be fulfilled by it, and no further action is required to be
performed by any Person with respect thereto other than payment thereon by the
applicable Obligor and no portion of which is in respect of any amount as to which
the related Obligor is permitted to withhold payment until the occurrence of a
specified event or condition (including “guaranteed” sales or any performance by any
other Persons),

          (h) The definition of “Transaction Documents” in Exhibit I to the Credit and Security
Agreement is hereby amended to include the agreements pursuant to which Acquired Receivables are
purchased and now read as follows:

          “Transaction Documents” means, collectively, this Agreement (including any Assignment
and Acceptance Agreements), each Borrowing Request, the Receivables Sale Agreement, each
Joinder Agreement, each Collection Account Agreement, the Amended Fee Letters, each of the
Subordinated Notes (as defined in the Receivables Sale Agreement), the Liquidity Agreements,
each asset purchase or other similar agreement pursuant to which Acquired Receivables are
purchased by a Seller (as defined in the Receivables Sale Agreement), and all other
instruments, documents and agreements executed and delivered in connection herewith.

          (i) The following new definition is hereby inserted in Exhibit I to the Credit and Security
Agreement in the appropriate alphabetical order and the new Exhibit XII referred in that definition
is added to the Credit and Security Agreement:

     “Acquired Receivables” means any right to payment arising from the sale to any
Domestic Person of medical products, devices or services by a Subsidiary of a Seller
(as defined in the Receivables Sale Agreement) listed on Exhibit XII (including,
without limitation, the right to payment of any interest or finance charges and
other amounts with respect thereto), which right has been acquired by such Seller
and as to which acquired right, the Seller has made (or caused to be made) all UCC
filings, and has taken (or caused to be taken) all such actions, necessary for such
Seller to acquire such right free and clear of any Lien except as created hereby or
by the other Transaction Documents .

          (j) The facility provided in the Credit and Security Agreement is hereby extended by amending
the following definitions in Exhibit I to the Credit and Security Agreement:

     “Liquidity Termination Date” means, for any Group, August 3, 2011 (unless such
date is extended from time to time in the sole discretion of the Liquidity Bank in
such Group).

     “Scheduled Termination Date” means, as to each Liquidity Bank, the earlier to
occur of August 3, 2011 and the date on which its Liquidity Commitment terminates in
accordance with the Liquidity Agreement to which it is a party, in

 

 

either of the
foregoing cases, unless extended by agreement of such Liquidity Bank accordance
with Section 1.8.

     2. Amendments to Receivables Sale Agreement.

          (a) Section 2.1(s) of the Receivables Sale Agreement is hereby amended by replacing the first
sentence thereof with the following:

Such Seller has instructed all Obligors thereon to pay all Collections (i) directly
by mail addressed to a Lockbox listed on Exhibit IV to the Credit and Security
Agreement which is subject to a Collection Account Agreement, (ii) by wire transfer
or other electronic funds transfer directly to a Collection Account listed on
Exhibit IV to the Credit and Security Agreement which is subject to a Collection
Account Agreement or (iii) in the case of the Collections of any Acquired
Receivables, to any lockbox or bank account to which Collections for such Acquired
Receivables were paid by the Obligors prior to such receivables becoming Acquired
Receivables, if any and all payments or balances in such lockbox or bank account on
any day are automatically transferred within two (2) Business Days to a Lockbox
listed on Exhibit IV to the Credit and Security Agreement which is subject to a
Collection Account Agreement or a Collection Account listed on Exhibit IV to the
Credit and Security Agreement which is subject to a Collection Account Agreement.

          (b) Section 4.1(h) of the Receivables Sale Agreement is hereby amended by replacing the period
at the end of the first sentence thereof with the following new proviso:

; provided that with respect to Acquired Receivables, such Seller may instruct the
Obligors thereof to continue to pay Collections to any lockbox or bank account to
which Collections for such Acquired Receivables were paid by the Obligors prior to
such receivables becoming Acquired Receivables, so long as any and all payments or
balances in such lockbox or bank account on any day are automatically transferred
within two (2) Business Days to a Lockbox listed on Exhibit IV to the Credit and
Security Agreement which is subject to a Collection Account Agreement or a
Collection Account listed on Exhibit IV to the Credit and Security Agreement which
is subject to a Collection Account Agreement.

          (c) Section 6.2(a) of the Receivables Sale Agreement is hereby amended by replacing the first
sentence thereof with the following:

Each Seller agrees to direct all Obligors to make payments of such Seller’s
Receivables directly to a Collection Account that is the subject of a Collection
Account Agreement at a Collection Bank or, in the case of such Seller’s Acquired
Receivables, to any lockbox or bank account to which Collections for such Acquired
Receivables were paid by the Obligors prior to such receivables becoming Acquired
Receivables, so long as any and all payments or balances in such lockbox or bank
account on any day are automatically transferred within two (2) Business Days to a
Lockbox listed on Exhibit IV to the Credit and Security

 

 

Agreement which is subject
to a Collection Account Agreement or a Collection Account listed on Exhibit IV to
the Credit and Security Agreement which is subject to a Collection Account
Agreement.

          (d) The definition of “Receivable” set forth in Annex A to the Receivables Sale Agreement is
hereby amended and restated in full to read as follows:

     “Receivable” means (a) any Acquired Receivable and (b) any right to payment
arising from the sale to any Domestic Person of medical products, devices or
services by a Seller, including, without limitation, the right to payment of any
interest or finance charges and other amounts with respect thereto, other than
Excluded Receivables. Rights to payment arising from any one transaction,
including, without limitation, rights to payment represented by an individual
invoice, shall constitute a Receivable separate from a Receivable consisting of the
rights to payment arising from any other transaction.

          (e) In each of the following sections of the Receivables Sale Agreement, the phrase
“Receivable(s) originated by any Seller” (or phrases of substantially the same content) shall be
deemed to be amended hereby to read “Receivables originated, or, in the case of any Acquired
Receivable(s), Receivable(s) purchased, by any Seller”: Sections 1.2(d), 1.4(a), 1.4(b), 2.1(o),
2.1(r), 2.1(t), 2.1(v), 4.1(c), 4.1(d), 4.1(f), 4.2(f), 4.3(a), 4.3(b), 4.3(c), 6.2(d), 6.3(a) and
7.1.

     3. Restatement of Amended Fee Letters.

          (a) The “Program Fee” (under and as defined in each of the Amended Fee Letters) is hereby
reset at the rate per annum specified in the restated Fee Letters entered into pursuant hereto.

          (b) The “Unused Fee” (under and as defined in each of the Amended Fee Letters) is hereby reset
at the rate per annum specified in the restated Fee Letters entered into pursuant hereto.

     4. Conditions Precedent to Effectiveness. The effectiveness of this Amendment is subject to
the conditions precedent that the Agents shall have received:

          (a) counterparts hereof duly executed by each of the parties hereto,

          (b) a copy of the proper financing statement (Form UCC-1) to be filed in the office of the
Secretary of State of the State of Delaware naming BSX as buyer and Boston Scientific
Neuromodulation Corporation as seller, in each case, describing in reasonable detail the Acquired
Receivable acquired by BSX pursuant to the Asset Purchase Agreement dated as of May 1, 2010 (the
“BSN APA”) between BSX and Boston Scientific Neuromodulation Corporation (“BSN”);

          (c) a written search report listing all effective UCC financing statements that name Boston
Scientific Neuromodulation Corporation as debtor, seller or assignor and that are filed in the
State of Delaware, together with copies of such financing statements (none of which, except for
those that have been terminated or described in the foregoing subsection (b), shall cover

 

 

any
Receivable or any Related Asset related to any Receivable which is to be sold or contributed by BSX
to the Borrower under the Receivables Sale Agreement);

          (d) UCC-3 financing statements amending the collateral descriptions in the UCC-1 financing
statements filed by BSX, as debtor, in favor of the Administrative Agent, and Borrower, as debtor,
in favor of the Administrative Agent, to reflect the amendments provided herein.

          (e) evidence of the execution and delivery by each of the parties thereto of the BSN APA;

          (f) its restated Fee Letter (reflecting the amendments thereto described in this Amendment),
dated as of the date hereof, duly executed by each of the parties thereto, together with the
Renewal Fee described therein;

          (g) Victory shall have received counterparts of an amendment to the Victory Liquidity
Agreement extending the term thereof to August 3, 2011; and

          (h) Old Line shall have received counterparts of an amendment to the Old Line Liquidity
Agreement extending the term thereof to August 3, 2011.

          The signatures of Victory and Old Line on counterparts of this Amendment shall constitute
confirmation that conditions (g) and (h), respectively, have been satisfied.

     5. Representations and Warranties. In order to induce the Conduits, the Liquidity Banks, the
Agents and the Administrative Agent to execute, deliver and perform this Amendment, the Loan
Parties hereby represent and warrant that (i) (1) each of the conditions precedent to the
effectiveness of the BSN APA has been satisfied or waived, (2) each party thereto has the corporate
power and authority, and has been duly authorized, to execute the BSN APA and to carry out the
transactions contemplated thereby and (3) the BSN APA is a legal, valid and binding obligation of
each party thereto, enforceable against such party in accordance with its terms, subject to
appropriate bankruptcy and public policy exceptions, (ii) BSN has instructed (i) the Obligors of
the Acquired Receivables sold by BSN under the BSN APA to pay all future Collections to a Lockbox
or Collection Account listed on Exhibit IV to the Credit and Security Agreement and (ii) the bank
holding the lockbox or account into which Collections on such Acquired Receivables are paid to
automatically transfer any such Collections to a Lockbox or Collection Account listed on Exhibit IV
to the Credit and Security Agreement and (iii) after giving effect to this Amendment, each of the
representations and warranties set forth in Section 6.1 of the Credit and Security Agreement (other
than Sections 6.1(b) and 6.1(g) thereof) and in Section 2.1 of the Receivables Sale Agreement
(other than Sections 2.1(b) and 2.1(g) thereof) is true and correct in all material respects on and
as of the date hereof (except for representations and warranties stated to refer to a specified
earlier date, in which case such representations and warranties are true and correct as of such
earlier date); provided that the preceding materiality standard shall not apply to those
representations and warranties which themselves contain materiality standards.

     6. Scope of Amendment. Except as expressly amended hereby, each of the Credit and Security
Agreement, the Receivables Sale Agreement and the Fee Letters remains in full force and effect in
accordance with its terms and this Amendment shall not by implication or otherwise

 

 

alter, modify,
amend or in any way affect any of the other terms, conditions, obligations, covenants or agreements
contained in the Credit and Security Agreement, the Receivables Sale Agreement or the Fee Letters,
all of which are ratified and affirmed in all respects and shall continue in full force and effect.

     7. Governing Law. This Amendment shall be governed by and construed in accordance with the
laws of the State of New York.

     8. Counterparts. This Amendment may be executed in any number of counterparts (including by
way of facsimile or electronic transmission) and each of such counterparts shall for all purposes
be deemed an original, and all such counterparts shall together constitute but one and the same
instrument.

<Signature pages follow>

 

 

EXECUTION COPY

          IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and
delivered by their duly authorized officers as of the date hereof.

	 	 	 	 	 
	 	BOSTON SCIENTIFIC FUNDING LLC

 	 
	 	By:  	 	 
	 	 	Name:  	Milan Kofol 	 
	 	 	Title:  	Treasurer 	 
	 
	 	BOSTON SCIENTIFIC CORPORATION, as Servicer and
Seller

 	 
	 	By:  	 	 
	 	 	Name:  	Milan Kofol 	 
	 	 	Title:  	Vice President, Treasurer 	 
	 

[Signature page to Amendment No. 3 to Amended and Restated Credit and Security Agreement]]

 

 

	 	 	 	 	 
	 	OLD LINE FUNDING, LLC

BY: ROYAL BANK OF CANADA, ITS

                ATTORNEY-IN-FACT

 	 
	 	 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	ROYAL BANK OF CANADA,

individually as a Liquidity Bank, as Old Line Agent and as
Administrative Agent

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

[Signature page to Amendment No. 3 to Amended and Restated Credit and Security Agreement]]

 

 

	 	 	 	 	 
	 	VICTORY RECEIVABLES CORPORATION

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., NEW YORK BRANCH, as a
Liquidity Bank

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	

 	 
	 
	 	THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., NEW YORK BRANCH, as
Victory Agent	 
	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

[Signature page to Amendment No. 3 to Amended and Restated Credit and Security Agreement]]

 

 

EXHIBIT XII

SUBSIDIARIES/SELLERS OF ACQUIRED RECEIVABLES

Boston Scientific Neuromodulation Corporationexv10w1

Exhibit 10.1

AGREEMENT AND GENERAL RELEASE

               Calgon Carbon Corporation, 400 Calgon Carbon Drive, Pittsburgh, Pennsylvania 15230-0717, on
behalf of itself and its Affiliates (as the term is defined in Rule 12b-2 under the Securities Act
of 1934, as amended), subsidiaries, divisions, successors and assigns and the past and present
employees, officers, directors and agents thereof (collectively referred to throughout this
Agreement as “Calgon”), and Leroy M. Ball (“Ball”) agree and intend to be legally bound by the
following:

          1. Last Day of Employment. Ball has tendered, and Calgon has accepted, his
resignation as Chief Financial Officer of Calgon, as President of Calgon Carbon Japan, and as an
employee of Calgon. Ball’s last day of employment with Calgon is as set forth in Paragraph 2 of
this Agreement. Ball and Calgon specifically agree that Ball’s service as Chief Financial Officer
of Calgon has terminated by his irrevocable resignation as of July 12, 2010, and that his
employment as a Senior Vice-President of Calgon, and as President of Calgon Carbon Japan, shall end
as of the date of the termination of employment as set forth in Paragraph 2 of this Agreement.
Further, by virtue of his execution of this Agreement, Ball hereby irrevocably tenders his
resignation as an officer and director of Calgon, and each of its subsidiaries and affiliates in
which he holds such a position, and Calgon may accept such resignations in due course as of the
effective date that Calgon shall determine.

          2. Consideration. In consideration for Ball signing and entering into this Agreement
and General Release (“Agreement”) and in compliance with the promises made herein, the parties
agree that:

          A. If Ball does not execute this Agreement, then his employment will end as of the earlier of
the date Ball notifies Calgon that he is not executing this Agreement, or the twenty-first (21st)
day after this Agreement is first provided to him. If Ball executes this Agreement, and then
revokes his acceptance of it within the revocation period provided in this Agreement, then his
employment with Calgon shall end as of the date of such revocation. In either event, Ball shall be
paid his regular base pay, minus required deductions, through his last date of employment.

          B. If Ball executes and does not revoke this Agreement, then he shall remain employed by
Calgon through August 31, 2010, as a Senior Vice President of Calgon. Calgon will pay Ball his
regular full base salary of $21,748.33 per month and continue to provide to him the employee
benefits generally applicable to Calgon employees through August 31, 2010. While so employed
through August 31, 2010, Ball shall be expected to provide limited transition services only as
specifically requested by Calgon and/or Calgon Carbon Japan, or any subsidiary or affiliate of
them. He shall comply with all of the policies and procedures of Calgon, work diligently and with
good faith to bring about the smooth transition of his work, and cooperate with the directives of
Calgon as it transitions duties, employees and related matters. He will also be expected to handle
special projects and other work assignments and answer business questions and/or attend business
meetings (which may require travel) as requested. If Calgon terminates Ball’s employment “for
cause,” or if Ball terminates his employment with Calgon

 

 

without Calgon’s consent prior to August 31, 2010, Ball’s right to the amounts, benefits and
representations contained in this Paragraph 2B, shall, at the election of Calgon, end as of the
date of termination. In the event that Ball becomes disabled during this period as defined by
Calgon’s plans regarding short term and long term disability, Ball may apply for disability
benefits consistent with those plans. Any disability leave, however, shall not affect Ball’s
termination date, pursuant to the terms of this Agreement. If Ball has executed this Agreement,
and has not revoked his acceptance of this Agreement, and has not terminated his employment by
Calgon prior to August 31, 2010 (except with the consent of Calgon), then Calgon agrees that Calgon
will treat Ball’s separation from his employment with Calgon as a “voluntary termination with the
consent of Calgon,” and therefore Calgon agrees that it will not make any demand under
Article III (or any provision of the same effect or import) of any of Ball’s Stock Option
Agreements with Calgon in an effort to have Ball forfeit the gain represented by the Fair Market
Value (as defined in the plan under which the award was granted) on the date of exercise over the
exercise price as set forth in the Stock Option Agreements. Calgon’s promise and agreement to
treat such separations as a “voluntary termination with the consent of Calgon” and/or to forbear
from making any demand shall be conditioned upon and only be effective if Ball has executed this
Agreement and has not revoked his acceptance of this Agreement.

               For purposes of this Paragraph 2B, termination shall be deemed “for cause” if among the
reasons therefore are: Ball’s dishonesty, disloyalty, willful misconduct, gross negligence,
refusal to perform his duties in good faith and to the best of his ability, breach of any of the
terms of this Agreement, breach of his duties to Calgon as set forth in any code of conduct adopted
by Calgon or engaging in conduct which has injured or would injure the business or reputation of
Calgon or would otherwise adversely affect Calgon’s interests.

          C. In consideration of this Agreement, and Calgon’s commitments hereunder, Ball further agrees
that he shall execute, date, and deliver, on or after August 31, 2010 and before September 14,
2010, to Richard Rose (or his successor) the Second Release attached to this Agreement. Because
Ball is receiving a copy of the Second Release with this Agreement, he acknowledges that he will
have had far in excess of 21 days to review and consider the Second Release, prior to August 31,
2010.

          D. The foregoing amounts, benefits and representations set forth in Paragraph “2B” shall
constitute full and complete satisfaction of any and all claims by Ball to compensation, severance,
bonus, and benefits of any kind or nature whatsoever. Specifically, Ball agrees that he is not
entitled to any other compensation, severance or benefits under the provisions of that certain
Employment Agreement between him and Calgon dated as of January 1, 2010, including but not limited
to any payment, severance or other compensation pursuant either of Paragraphs 4 or 5 of that
Employment Agreement (“Employment Agreement”), under any other agreement.

          3. No Consideration Absent Execution of this Agreement. Ball understands and agrees
that he would not receive benefits and/or the monies specified in Paragraph “2B” above, except for
his execution of this Agreement and his fulfillment of the promises contained herein.

          4. General Release of Claims. Ball knowingly and voluntarily releases and forever
discharges Calgon, its Affiliates (as the term is defined in Rule 12b-2 under the Securities Act of
1934, as amended), subsidiaries, divisions, successors and assigns, and the past and present

2

 

employees, officers, directors and agents thereof (collectively referred to throughout this
Agreement as “Releasees”), of and from any and all claims, demands, liabilities, obligations,
promises, controversies, damages, rights, actions and causes of action, known and unknown, which
Ball, his heirs, executors, administrators, successors, and assigns (referred to collectively
throughout this Agreement as “Ball”) has or may have against Releasees as of the date of Ball’s
signing of this Agreement, including, but not limited to, any alleged violation of:

	 	•	 	Title VII of the Civil Rights Act of 1964, as amended;
	 
	 	•	 	The Civil Rights Act of 1991;
	 
	 	•	 	Sections 1981 through 1988 of Title 42 of the United States Code, as amended;
	 
	 	•	 	The Employee Retirement Income Security Act of 1974, as amended;
	 
	 	•	 	The Immigration Reform and Control Act, as amended;
	 
	 	•	 	The Americans with Disabilities Act of 1990, as amended;
	 
	 	•	 	The Age Discrimination in Employment Act of 1967, as amended;
	 
	 	•	 	The Older Workers Benefit Protection Act;
	 
	 	•	 	The Sarbanes-Oxley Act of 2002;
	 
	 	•	 	The National Labor Relations Act;
	 
	 	•	 	The Family and Medical Leave Act, as amended;
	 
	 	•	 	Pennsylvania Human Relations Act;
	 
	 	•	 	Pennsylvania Wage Payment and Collection Law;
	 
	 	•	 	Pittsburgh City Code, Chapters 651-659;
	 
	 	•	 	The Occupational Safety and Health Act, as amended;
	 
	 	•	 	The Equal Pay Act of 1963;
	 
	 	•	 	Any other federal, state or local civil or human rights law or any other local, state or
federal law, regulation or ordinance;
	 
	 	•	 	Any public policy, contract, tort or common law; or
	 
	 	•	 	Any claims for costs, fees, or other expenses including attorneys’ fees incurred in
these matters (all of the above collectively referred to as “Claims”).

          This release is intended to be a general release, and excludes only those claims under any
statute or common law that Ball is legally barred from releasing. Ball is advised to seek
independent legal counsel if Ball seeks clarification on the scope of this release.

          This release does not include any claims relating to or arising from Ball’s enforcement of
this Agreement or for any benefits vested under any Calgon-sponsored employee benefit plan (other
than severance benefits), or for any unemployment compensation benefits.

          5. No Claims Exist and No Recovery or Relief. Ball confirms that no claim, charge,
complaint, or action exists in any forum or form brought by him or on his behalf against Releasees.
Nothing herein is intended to or shall preclude Ball from filing a complaint and/or charge with an
appropriate federal, state or local government agency and/or cooperating with said agency in its
investigation (“Agency Charge”). In the event that any Agency Charge is filed by Ball or on his
behalf against Releasees related to any matter released herein in this Agreement, Ball waives his
right to recover any monetary relief or monetary recovery therefrom, including costs and attorneys’
fees.

3

 

          Nothing herein is intended to or shall preclude Ball from challenging the validity of this
Agreement. Ball affirms that he has been paid and/or has received all compensation, benefits,
vacation, wages, bonuses, commission and/or benefits due to him except as provided in this
Agreement. Ball furthermore affirms that he has no known workplace injuries or occupational
diseases and has been provided and/or has not been denied any leave requested. Ball further
affirms that he has not been retaliated against for reporting violations of wrongdoing by Calgon or
its officers, including any allegations of corporate fraud.

          6. Confidential Information. Ball acknowledges that all knowledge and information
which he acquired in the course of his employment with Calgon relating to Calgon’s financial
information and data, marketing data or information, customer identities and business information,
compensation and benefits information, information about Calgon’s employees, and Calgon’s policies,
practices and procedures (hereinafter collectively referred to as “Confidential Information”) are
the valuable property of Calgon. Ball agrees not to disclose, divulge, or publish to any person or
non-governmental entity, any of the aforementioned Confidential Information recognizing that this
would cause irreparable harm to Calgon. In the event that Ball is legally compelled to disclose
any materials, including Confidential Information of Calgon’s or any of its Affiliates pursuant to
a subpoena, or any other lawful process, from a non-governmental person or entity, Ball agrees that
he shall provide Calgon with prompt notice of such subpoena or process. Calgon may seek an
appropriate protective order or other remedy; may consult with Ball with respect to the nature and
scope of the information he proposes to disclose, as well as steps he may take to resist or narrow
the scope of such request or legal process; or may waive compliance, in whole or in part, with this
Paragraph 6 of this Agreement. Ball shall use his best efforts to ensure that any Confidential
Information that is disclosed by him will be accorded confidential treatment by its recipient or
recipients. Ball shall return any materials, including Confidential Information obtained,
developed or received by him during the course of his employment with Calgon (including, but not
limited to, all originals and copies of any materials and documents which refer or relate to
Calgon’s financial status, business, employees, clients or projects) within seven (7) days of the
last day on which he provides the limited transition services as described in Paragraph 2(B), but
in no event later than September 7, 2010.

          7. Trade Secrets. Ball further agrees not to disclose to any person or entity,
including any governmental entity, any Trade Secrets of Calgon, without the express, written
consent of Calgon. Trade Secrets, as that term is used in this Agreement, shall mean information
(including customer lists, programs, devices, methods, techniques or processes) that derives
independent economic value, actual or potential, from not being readily ascertainable by proper
means by other persons who could obtain economic value for its disclosure or use, and which is the
subject of reasonable means, under the circumstances, by Calgon to keep it secret. In the event
that Ball is legally compelled to disclose any Trade Secrets of Calgon’s or any of its Affiliates
pursuant to a subpoena, civil investigative demand, regulatory demand, or pursuant to applicable
law, Ball agrees that he shall provide Calgon with prompt notice of such request or requirement as
well as a copy of the description of the Trade Secrets that he proposes to disclose as far in
advance of such disclosure as is reasonably practicable. Calgon may seek an appropriate protective
order or other remedy; may consult Ball with respect to the nature and scope of the information he
proposes to disclose, as well as steps he may take to resist or narrow the scope of such request or
legal process; or may waive compliance, in whole or in part, with

4

 

this Paragraph 7 of this Agreement. Ball agrees not to oppose any action by Calgon to obtain
a protective order or other appropriate remedy. In the event that no such protective order is
obtained, or that Calgon waives compliance with this Paragraph 7, Ball shall use his best efforts
to ensure that any Trade Secrets that are disclosed will be accorded confidential treatment.

          8. Cooperation. Ball agrees to be reasonably available to Calgon and the Releasees
for the purpose of responding to requests for information concerning Calgon’s and its Affiliate’s
business or work performed by Ball, and to provide information, documents, declarations or
statements, and to meet with attorneys and other Ball representatives, to prepare for and give
depositions or testimony, and/or to otherwise cooperate in the investigation, regulatory matters,
proceeding or investigations, defense or prosecution of matters relating to any threatened,
present, or future legal action, investigations or administrative proceedings involving the
Releasees and their Affiliates. Calgon will advance or reimburse Ball’s reasonable out-of-pocket
costs, actually incurred, as a result of Ball’s obligations under this provision.

          9. No Participation in Private Claims. Ball understands that if this Agreement were
not signed, Ball would have the right to voluntarily assist other individuals or non-government
entities in bringing claims against Calgon. Ball further understands and agrees that he waives any
such right and will not provide any such assistance, except Ball may provide information pursuant
to any valid subpoena or compulsory process, and Ball may participate in any Agency Charge as set
forth in Paragraph 5.

          10. Future Employment. Ball agrees and understands that he will not be employed by
Calgon in the future, except in the sole and exclusive discretion of Calgon.

          11. Noncompetition and Nonsolicitation.

          (a) Ball agrees that for a three-year period following the date of his termination of
employment he will not directly or indirectly (either himself or with, through or in assistance to
a future employer or other entity or person) induce or attempt to induce any Calgon Employee to
terminate employment, nor will he hire or participate in the hiring or interviewing of any Calgon
Employee for or by any other firm, entity, person or organization; nor will he provide the names or
other information about Calgon’s Employees for the purpose of assisting others to hire such Calgon
Employees; nor will he provide information to a Calgon Employee about his employer or any company
or entity affiliated with his employer for the purpose of assisting that Calgon Employee in finding
employment with such entity. For purposes of this Paragraph 11, a “Calgon Employee” means anyone
who is or has been employed by Calgon or its Affiliates (as the term is defined in Rule 12b-2 under
the Securities Act of 1934, as amended), within one hundred miles of Pittsburgh, Pennsylvania or in
the nation of Japan (or employed by Calgon elsewhere but having principal duties related to
Calgon’s business in Japan), unless such person has ceased working for Calgon for a period in
excess of six (6) months prior to Ball’s inducement of, utilization of services of, participation
in the hiring or interviewing of, or providing information about or to such person. Ball agrees
that if any future employer of his hires or retains or receives the services of a Calgon Employee
during the above-stated three-year period, it shall be conclusively presumed that such hiring or
retention occurred in violation of this paragraph.

5

 

          (b) Ball agrees that during the same three-year period, he shall not, directly or indirectly,
on his own behalf or on behalf of or in conjunction with any other person or entity, solicit the
trade of, or trade with, any customers or suppliers, or prospective customers or suppliers, of
Calgon.

          (c) In light of the consideration being provided to Ball under this Agreement, and the duties,
responsibilities and access provided of and by the positions Ball held while employed by Calgon,
Ball further agrees that during this same three-year period, he will not, directly or indirectly,
engage in any employment or other activity that is in competition with the business of Calgon
(“Competing Business”), in any capacity, including but not limited to, as an employee, principal,
agent, officer, director, shareholder, consultant, contractor or otherwise , nor shall he engage in
any activity during that period which assists or supports any other person or entity to engage in
such Competing Business, as to or in any Competitive Territory. This includes but is not limited
to his employment by, or rendering service in any form to, any entity, organization or other person
that is engaged in such activity. The term “Competing Business” shall mean any person,
corporation, or other entity which sells or attempts to sell any products or services which are the
same as or similar to the products and services sold by Calgon at any time and from time to time
during the last two years prior to the termination of Ball’s employment or which were contemplated
by any of Calgon’s business or strategic plans at any time during Ball’s employment by Calgon. The
term “Competitive Territory” shall mean the United States of America, Great Britain, Belgium,
Germany, Japan, China, and any other nation or location in which Calgon has made, or considered
making, such sales, either itself or through a subsidiary, affiliate, or joint venture partner,
during the last two years prior to the termination of Ball’s employment and/or during that
three-year period applicable to this provision. Prior to accepting employment, or service or
appointment to any of the above-enumerated positions, during the three-year period set forth above,
Ball shall notify Calgon in order for Calgon to determine if the position that Ball is considering
violates this Agreement. The decision of Calgon in these regards shall be considered final and
binding.

          12. No Negative or Derogatory Comments. Except as may be expressly permitted by the
provisions of Paragraph 5 of this Agreement, Ball agrees to make no negative or derogatory
comments, directly or by innuendo, about Calgon’s officers, employees or directors, or its business
practices and philosophies, or Calgon’s products or services in any business or social setting.
Calgon agrees that it will advise and direct its Named Executive Officers (as that term is defined
in Item 402 of Regulation SK and as set forth in the proxy statement for Calgon’s Annual Meeting of
April 22, 2010) to not make negative or derogatory comments about Ball to any person or entity,
except as may be required in order to comply with legal or regulatory requirements.

          13. Governing Law and Interpretation. This Agreement shall be governed and conformed
in accordance with the laws of the Commonwealth of Pennsylvania without giving effect to the
principles of conflict of laws. Ball hereby irrevocably submits to the personal and exclusive
jurisdiction of the United States District Court for the Western District of Pennsylvania or the
Court of Common Pleas of Allegheny County, Pennsylvania in any action or proceeding arising out of,
or relating to, this Agreement (whether such action arises under contract, tort, equity or
otherwise). Ball hereby irrevocably waives any objection which Ball now or hereafter may have to
the laying of venue or personal jurisdiction of any such action or proceeding

6

 

brought in said courts. Jurisdiction and venue of all such causes of action shall be
exclusively vested in the United States District Court for the Western District of Pennsylvania or
the Court of Common Pleas of Allegheny County, Pennsylvania. Ball irrevocably waives his right to
object to or challenge the above selected forum on the basis of inconvenience or unfairness under
28 U.S.C. § 1404, 42 Pa. C.S. § 5322 or similar state or federal statutes. Should Ball challenge
or object to personal jurisdiction or venue in Allegheny County, Pennsylvania, Ball agrees to
reimburse Calgon for all attorneys’ fees and costs it incurs to oppose Ball’s efforts to challenge
or object to personal jurisdiction on venue identified in this Paragraph.

          14. Severability. If any term, provision or paragraph of this Agreement is determined
by a court of competent jurisdiction to be invalid or unenforceable for any reason, such
determination shall be limited to the narrowest possible scope in order to preserve the
enforceability of the remaining portions of the term, provision or paragraph, and such
determination shall not affect the remaining terms, provisions or paragraphs of this Agreement,
which shall continue to be given full force and effect.

          15. Nonadmission of Wrongdoing. Ball agrees that neither this Agreement nor the
furnishing of the consideration for this Release shall be deemed or construed at any time for any
purpose as an admission by Calgon or any Releasee of any liability or unlawful conduct of any kind.

          16. Amendment. This Agreement may not be modified, altered or changed except upon
express written consent of both Parties wherein specific reference is made to this Agreement.

          17. Entire Agreement. Except as stated in this Agreement, this Agreement represents
the entire agreement of the parties with respect to the subject matter hereof. To the extent Ball
previously entered into an enforceable agreement with Calgon that contains provisions that are not
in direct conflict with provisions in this Agreement, the terms of this Agreement shall not
supersede, but shall be in addition to, any other such agreement. Ball expressly agrees that the
provisions of Paragraphs 7 (a) and (b), 8(a) and (b), and 9 (which Paragraph 9 shall be applicable
to this Agreement and to the Employment Agreement) of the Employment Agreement shall remain in full
effect. Ball acknowledges that he has not relied on any representations, promises, or agreements
of any kind made to him in connection with his decision to sign this Agreement, except for those
set forth in this Agreement. Ball further represents and acknowledges that the only representative
of Calgon who has the authority to make statements about the content of this Agreement is Richard
Rose (or his successor).

          18. Evaluation of Agreement. Ball acknowledges that he is hereby advised in writing
to consult an attorney of his choice about this Agreement. Ball further acknowledges that he has
been given twenty one (21) days to consider the terms of this Agreement, and to consult with
counsel concerning its terms. If Ball executes this Agreement prior to expiration of the twenty
one (21) day period, he acknowledges that he does so freely and voluntarily, solely because he
already fully and carefully considered the Agreement before signing it. If Ball does not accept
this Agreement by signing and returning it to Richard Rose, Vice-President, General Counsel and
Corporate Secretary, on or before the twenty-first (21st) day after it is delivered to

7

 

him by Calgon, the terms contained in this Agreement will be automatically withdrawn by Calgon
without further action by Calgon.

          19. Time to Revoke. Ball hereby acknowledges that he has also been informed that for
a period of seven (7) days following his signing this Agreement, he may revoke his acceptance in
writing, and this Agreement will not be effective until such seven (7) day period has expired. If
such 7th day is a Saturday, Sunday, or legal holiday, then any revocation may not be
delivered until the next following day which is not a Saturday, Sunday, or legal holiday. Any
revocation within this period must be submitted in writing to Richard Rose, Vice-President, General
Counsel and Corporate Secretary, stating “I hereby revoke my acceptance of my Agreement.” If Ball
revokes in writing, Ball will not receive the consideration referred to in this Agreement. If he
does not revoke this Agreement, it shall become irrevocable after the expiration of this
7th day.

BALL HAS BEEN ADVISED THAT HE HAS TWENTY ONE (21) CALENDAR DAYS TO CONSIDER THIS AGREEMENT AND
SEVEN (7) CALENDAR DAYS TO REVOKE AFTER EXECUTION. BALL ALSO IS ADVISED TO CONSULT WITH AN
ATTORNEY PRIOR TO HIS SIGNING OF THIS AGREEMENT.

BALL AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT DO NOT RESTART OR
AFFECT IN ANY MANNER THE ORIGINAL TWENTY ONE (21) CALENDAR DAY CONSIDERATION PERIOD.

HAVING ELECTED TO EXECUTE THIS AGREEMENT, TO FULFILL THE PROMISES SET FORTH HEREIN, AND TO RECEIVE
THEREBY THE SUMS AND BENEFITS SET FORTH IN PARAGRAPH “2” ABOVE, BALL FREELY AND KNOWINGLY, AND
AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL
CLAIMS HE HAS OR MIGHT HAVE AGAINST CALGON.

	 	 	 	 	 	 	 	 	 	 	 

	 	 	Witness:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	/s/ Richard D. Rose	 	 	 	/s/ Leroy M. Ball	 	 
	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Leroy M. Ball	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	8/4/10	 	 	 	8/4/10	 	 
	 	 	 	 	 	 	 	 	 
	 	 	Date	 	 	 	Date	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	Attest:	 	 	 	CALGON CARBON CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Richard D. Rose
	 	 	 	/s/ John S. Stanik	 	 
	 

	 	 	 	 
	 	 	 	 	 	 
	 

	 	 	 	V.P., General Counsel & Secretary	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Title: President & CEO	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Date: 8/4/10	 	 

8

 

SECOND RELEASE

               Calgon Carbon Corporation, 400 Calgon Carbon Drive, Pittsburgh, Pennsylvania 15230-0717, on
behalf of itself and its Affiliates (as the term is defined in Rule 12b-2 under the Securities Act
of 1934, as amended), subsidiaries, divisions, successors and assigns and the past and present
employees, officers, directors and agents thereof (collectively referred to throughout this Second
Release as “Calgon”), and Leroy M. Ball (“Ball”) agree and intend to be legally bound by the
following:

          1. Last Day of Employment. Ball’s last day of employment with Calgon shall be August
31, 2010.

          2. Consideration. Ball acknowledges and agrees that in conjunction with the
consideration to be provided to him under that certain Agreement and General Release executed by
Ball on                     , (“Agreement”), he has agreed to execute this Second Release.

          3. Timing of Execution of Second Release is of the Essence. Ball understands that he
has agreed to execute this Second Release on or after August 31, 2010 and on or before September
14, 2010, and hand deliver it to Richard Rose, or his successor.

          4. Time to Revoke. Ball hereby acknowledges that he has also been informed that for a
period of seven (7) days following his signing this Second Release, he may revoke his acceptance in
writing, and this Second Release will not be effective until such seven (7) day period has expired.
If such 7th day is a Saturday, Sunday, or legal holiday, then any revocation may not be
delivered until the next following day which is not a Saturday, Sunday, or legal holiday. Any
revocation within this period must be submitted in writing to Richard Rose, Vice-President, General
Counsel and Corporate Secretary, stating “I hereby revoke my acceptance of my Second Release.” If
Ball revokes in writing, Ball will not receive the consideration referred to in this Second
Release. If he does not revoke this Second Release, it shall become irrevocable after the
expiration of this 7th day.

          5. General Release of Claims. Ball knowingly and voluntarily releases and forever
discharges Calgon, its Affiliates (as the term is defined in Rule 12b-2 under the Securities Act of
1934, as amended), subsidiaries, divisions, successors and assigns, and the past and present
employees, officers, directors and agents thereof (collectively referred to throughout this Second
Release as “Releasees”), of and from any and all claims, demands, liabilities, obligations,
promises, controversies, damages, rights, actions and causes of action, known and unknown, which
Ball, his heirs, executors, administrators, successors, and assigns (referred to collectively
throughout this Agreement as “Ball”) has or may have against Releasees as of the date of Ball’s
signing of this Second Release, including, but not limited to, any alleged violation of:

	 	•	 	Title VII of the Civil Rights Act of 1964, as amended;
	 
	 	•	 	The Civil Rights Act of 1991;
	 
	 	•	 	Sections 1981 through 1988 of Title 42 of the United States Code, as amended;
	 
	 	•	 	The Employee Retirement Income Security Act of 1974, as amended;
	 
	 	•	 	The Immigration Reform and Control Act, as amended;
	 
	 	•	 	The Americans with Disabilities Act of 1990, as amended;

9

 

	 	•	 	The Age Discrimination in Employment Act of 1967, as amended;
	 
	 	•	 	The Older Workers Benefit Protection Act;
	 
	 	•	 	The Sarbanes-Oxley Act of 2002;
	 
	 	•	 	The National Labor Relations Act;
	 
	 	•	 	The Family and Medical Leave Act, as amended;
	 
	 	•	 	Pennsylvania Human Relations Act;
	 
	 	•	 	Pennsylvania Wage Payment and Collection Law;
	 
	 	•	 	Pittsburgh City Code, Chapters 651-659;
	 
	 	•	 	The Occupational Safety and Health Act, as amended;
	 
	 	•	 	The Equal Pay Act of 1963;
	 
	 	•	 	Any other federal, state or local civil or human rights law or any other local, state or
federal law, regulation or ordinance;
	 
	 	•	 	Any public policy, contract, tort or common law; or
	 
	 	•	 	Any claims for costs, fees, or other expenses including attorneys’ fees incurred in
these matters (all of the above collectively referred to as “Claims”).

          This Second Release is intended to be a general release, and to cover any period after Ball
has executed the Agreement, and excludes only those claims under any statute or common law that
Ball is legally barred from releasing. Ball is advised to seek independent legal counsel if Ball
seeks clarification on the scope of this release.

          This Second Release does not include any claims relating to or arising from Ball’s enforcement
of this Second Release or for any benefits vested under any Calgon-sponsored employee benefit plan
(other than severance benefits), or for any unemployment compensation benefits.

          6. No Claims Exist and No Recovery or Relief. Ball confirms that no claim, charge,
complaint, or action exists in any forum or form brought by him or on his behalf against Releasees.
Nothing herein is intended to or shall preclude Ball from filing a complaint and/or charge with an
appropriate federal, state or local government agency and/or cooperating with said agency in its
investigation (“Agency Charge”). In the event that any Agency Charge is filed by Ball or on his
behalf against Releasees related to any matter released herein this Second Release, Ball waives his
right to recover any monetary relief or monetary recovery therefrom, including costs and attorneys’
fees.

          Nothing herein is intended to or shall preclude Ball from challenging the validity of this
Second Release. Ball affirms that he has been paid and/or has received all compensation, benefits,
vacation, wages, bonuses, commission and/or benefits due to him except as provided in this Second
Release. Ball furthermore affirms that he has no known workplace injuries or occupational diseases
and has been provided and/or has not been denied any leave requested. Ball further affirms that he
has not been retaliated against for reporting violations of wrongdoing by Calgon or its officers,
including any allegations of corporate fraud.

          7. Affirmation to Remain Bound. Ball specifically agrees to remain bound by the
Confidential Information, Confidentiality, Noncompetition and Nonsolicitation, Trade Secrets, No
Participation in Private Claims, and No Negative or Derogatory Comments provisions in the

10

 

Agreement that he previously executed with Calgon, and each of those provisions is
incorporated herein by reference. Notwithstanding anything in this Second Release to the contrary,
that Agreement shall remain in full force and effect according to its terms. Nothing herein is
intended to or shall preclude Ball from filing a complaint and/or charge with any appropriate
federal, state, or local government agency and/or cooperating with said agency in its
investigation. Ball, however, shall not be entitled to receive any relief, recovery, or monies in
connection with any complaint or charge brought against Releasees, without regard as to who brought
any said complaint or charge.

          8. Governing Law and Interpretation. This Second Release shall be governed and
conformed in accordance with the laws of the Commonwealth of Pennsylvania without giving effect to
the principles of conflict of laws. Ball hereby irrevocably submits to the personal and exclusive
jurisdiction of the United States District Court for the Western District of Pennsylvania or the
Court of Common Pleas of Allegheny County, Pennsylvania in any action or proceeding arising out of,
or relating to, this Second Release (whether such action arises under contract, tort, equity or
otherwise). Ball hereby irrevocably waives any objection which Ball now or hereafter may have to
the laying of venue or personal jurisdiction of any such action or proceeding brought in said
courts. Jurisdiction and venue of all such causes of action shall be exclusively vested in the
United States District Court for the Western District of Pennsylvania or the Court of Common Pleas
of Allegheny County, Pennsylvania. Ball irrevocably waives his right to object to or challenge the
above selected forum on the basis of inconvenience or unfairness under 28 U.S.C. § 1404, 42 Pa.
C.S. § 5322 or similar state or federal statutes. Should Ball challenge or object to personal
jurisdiction or venue in Allegheny County, Pennsylvania, Ball agrees to reimburse Calgon for all
attorneys’ fees and costs it incurs to oppose Ball’s efforts to challenge or object to personal
jurisdiction on venue identified in this Paragraph.

          9. Nonadmission of Wrongdoing. The Parties agree that neither this Second Release nor
the furnishing of the consideration for this Second Release shall be deemed or construed at anytime
for any purpose as an admission by Releasees, or evidence of any liability or unlawful conduct of
any kind.

          10. Amendment. This Second Release may not be modified, altered or changed except in
writing and signed by both parties wherein specific reference is made to this Second Release.

          11. Severability. If any term, provision or paragraph of this Second Release is
determined by a court of competent jurisdiction to be invalid or unenforceable for any reason, such
determination shall be limited to the narrowest possible scope in order to preserve the
enforceability of the remaining portions of the term, provision or paragraph, and such
determination shall not affect the remaining terms, provisions or paragraphs of this Second
Release, which shall continue to be given full force and effect.

          12. Entire Agreement. Subject to Paragraph 8 of this Second Release, this Second
Release sets forth the entire agreement between the parties with respect to the subject matter
hereof. To the extent Ball has entered into an enforceable agreement with Calgon that contains
provisions that are not in direct conflict with provisions in this Second Release, the terms of
this Second Release shall not supersede, but shall be in addition to, any other such agreement.
Ball

11

 

acknowledges that he has not relied on any representations, promises, or agreements of any
kind made to him in connection with his decision to accept this Second Release, except for those
set forth in this Second Release. Ball further represents and acknowledges that the only
representative of Calgon who has the authority to make statements about the content of this Second
Release is Richard Rose (or his successor).

               BALL HAS BEEN ADVISED THAT HE HAS AT LEAST TWENTY-ONE (21) CALENDAR DAYS TO CONSIDER THIS
SECOND RELEASE (SAID 21 DAYS OCCURRING PRIOR TO AUGUST 31, 2010) AND HAS BEEN ADVISED IN WRITING TO
CONSULT WITH AN ATTORNEY PRIOR TO EXECUTION OF THIS SECOND RELEASE.

               BALL AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS SECOND RELEASE DO NOT
RESTART OR AFFECT IN ANY MANNER THE ORIGINAL TWENTY-ONE (21) CALENDAR DAY CONSIDERATION PERIOD.

               HAVING ELECTED TO EXECUTE THIS SECOND RELEASE, TO FULFILL THE PROMISES SET FORTH HEREIN, AND
TO RECEIVE THEREBY THE BENEFITS SET FORTH IN PARAGRAPH “2” ABOVE, BALL FREELY AND KNOWINGLY, AND
AFTER DUE CONSIDERATION, ENTERS INTO THIS SECOND RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL
CLAIMS HE HAS OR MIGHT HAVE AGAINST RELEASEES.

               IN WITNESS WHEREOF, the parties hereto knowingly and voluntarily executed this Second Release
as of the date set forth below:

	 	 	 	 	 	 	 	 	 	 	 

	Witness:	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	Leroy M. Ball	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Date	 	 	 	Date	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Attest:	 	 	 	CALGON CARBON CORPORATION.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Date:	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]